The properties of interleukin-l suggest that it has a central role in the immunopathology of many arthritides (figure). It is now more than 10 years since it was realised that numerous biological activities were due to a single agent called interleukin-I (IL-I)' (now known to be two related proteins, IL-la and IL-l132). The functions of IL-1, such as T cell activation,3 stimulation of cellular production of prostaglandin E2 and I2,4 interleukin-1,5 and interleukin-6,6 help for B cell growth,7 induction of endothelial cell adhesion molecule expression,8 stimulation of chondrocyte stromelysin,9 synovial cell collagenase, and plasminogen activator production,'0-'2 induction of bone resorption,'3 and hepatic acute phase protein synthesis, show its enormous potential for mediating pathological processes. The 10th birthday of this 'first interleukin' was recently celebrated in a comprehensive review of our current knowledge by di Giovine and Duff. 14 
Interleukin-1: a complex biological system CONTROL OF PRODUCTION Interleukin-la and IL-1iB protein production is controlled at several levels, including gene transcription, messenger RNA (mRNA) stability, translation to form the 31 kd precursor protein, and release of the processed mature 17-5 kd protein. '5 The complexity of IL-1 production is illustrated by the high concentrations of IL-1 mRNA that can be stimulated by adherence of monocytes to glass. 6 This mRNA is not translated into protein, however, unless a second signal (usually endotoxin) is supplied. Human monocytes are very sensitive to endotoxin and can produce IL-I in response to the low concentrations commonly found in tissue culture media. 6 Both endotoxin and IL-I stimulate transcription and translation of IL-i.5 Glucocorticoids can reduce IL-I transcription and translation,17 18 in contrast with prostaglandins, which reduce translation without changing gene transcription. ' arthritis a possible mechanism relating cytokines to disease might be an initial insult to cartilage with release of cartilage fragments which then stimulate synovial lining cell production of IL-1. The properties of IL-1 may then contribute to the progress of the lesion. In this situation the balance of cytokine and inhibitor would play a crucial part.
The importance of IL-I (and other cytokine) secretion in the early stages of disease will be best studied in animal models.8' Interleukin-I has been detected in the synovial fluid of equine osteoarthritis.82 Two facts suggest this is an important point to resolve. Glucocorticoids have been shown to prevent progression of disease in osteoarthritis models, in contrast with non-steroidal anti-inflammatory drugs, which have no effect. Glucocorticoids have many effects, including reduction of collagenase production, which may mediate this improvement. It must be remembered that another powerful activity is the reduction of cytokine expression. The second fact relates to reports that non-steroidal anti-inflammatory drugs, which reduce prostaglandin concentrations, may cause a more rapid deterioration of osteoarthritis. 83 The mechanisms by which this might occur are unclear but, possibly, suppression of the prostaglandin negative feedback on IL-1 production may contribute to this deterioration
Conclusion
The increasing in vivo definition of cytokine activities and distribution promises to provide the clinician with explanations of disease pathology. Important lessons about the ease of non-physiological stimulation of cells (recently illustrated by the in vitro production of tumour necrosis factor a in patient samples84) mean that clinical studies must be meticulously planned and executed if meaningful data are to be gained. With the availability of ultrasensitive techniques using the polymerase chain reaction to detect very low concentrations of cytokine mRNA85 the complex control of production of many cytokines must be remembered, and cytokine production should preferably be reported at both the mRNA and peptide level. The recombinant materials, specific monoclonal antibodies, and techniques are now available to ensure a continuation of the recent encouraging increase of studies to define in vivo cytokine function.
The findings for IL-l described in this review give an indication of the potential available information but have little meaning in isolation. A more complete picture of the cytokine network that operates in many diseases will emerge when the range of cytokines is assessed at the site of disease activity. It may become apparent that there is a hierarchy of cytokines in different diseases which might be regulated by inhibiting the actions of a limited number of cytokines. At present the great overlap of cytokine activities suggests to many in this field that this will not be the case. An interesting hypothesis would suggest that so called 'non-inflammatory' diseases such as osteoarthritis, which may have a limited number of participating cytokines, may be more appropriate targets for these immunotherapies of the future. There is more than one interleukin 1. Immunol Today 1986; 7: 45-56. 3 Herrmann A F, Oster W, Meuer S C, Lindemann A,
